CD276 and cancer: In addition, previous studies indicated that STAT3 (Li et al., 2017; Shi et al., 2019), ERK (Li et al., 2017), p53 (Son et al., 2019), c-Myc (Zhang et al., 2019), TGF-β (Zhang et al., 2019), and NF-kappaB (p65) (Xie et al., 2016) signaling pathways are the downstream targets of B7H3 in cancers.